These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34584129)

  • 21. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
    de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
    Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term weight-loss in gastric bypass patients carrying melanocortin 4 receptor variants.
    Moore BS; Mirshahi UL; Yost EA; Stepanchick AN; Bedrin MD; Styer AM; Jackson KK; Still CD; Breitwieser GE; Gerhard GS; Carey DJ; Mirshahi T
    PLoS One; 2014; 9(4):e93629. PubMed ID: 24705671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
    Fujishima Y; Maeda N; Inoue K; Kashine S; Nishizawa H; Hirata A; Kozawa J; Yasuda T; Okita K; Imagawa A; Funahashi T; Shimomura I
    Cardiovasc Diabetol; 2012 Sep; 11():107. PubMed ID: 22973968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dietary Protein Modifies the Effect of the
    Huang T; Zheng Y; Hruby A; Williamson DA; Bray GA; Shen Y; Sacks FM; Qi L
    J Nutr; 2017 Mar; 147(3):439-444. PubMed ID: 28148682
    [No Abstract]   [Full Text] [Related]  

  • 25. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
    Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
    Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.
    Kadouh H; Chedid V; Halawi H; Burton DD; Clark MM; Khemani D; Vella A; Acosta A; Camilleri M
    J Clin Endocrinol Metab; 2020 May; 105(5):1552-63. PubMed ID: 31665455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melanocortin-4 Receptor Gene Mutations in a Group of Turkish Obese Children and Adolescents.
    Tunç S; Demir K; Tükün FA; Topal C; Hazan F; Sağlam B; Nalbantoğlu Ö; Yıldız M; Özkan B
    J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):216-221. PubMed ID: 28218067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Weight Outcome After Bariatric Surgery in Patients with Melanocortin-4 Receptor Gene Variants: a Case-Control Study of 105 Patients.
    Cooiman MI; Alsters SIM; Duquesnoy M; Hazebroek EJ; Meijers-Heijboer HJ; Chahal H; Le Beyec-Le Bihan J; Clément K; Soula H; Blakemore AI; Poitou C; van Haelst MM
    Obes Surg; 2022 Mar; 32(3):837-844. PubMed ID: 34984630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection.
    Page LC; Freemark M
    Curr Obes Rep; 2020 Dec; 9(4):391-401. PubMed ID: 33085056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lifestyle intervention in obese children with variations in the melanocortin 4 receptor gene.
    Reinehr T; Hebebrand J; Friedel S; Toschke AM; Brumm H; Biebermann H; Hinney A
    Obesity (Silver Spring); 2009 Feb; 17(2):382-9. PubMed ID: 18997677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes.
    Quast DR; Nauck MA; Schenker N; Menge BA; Kapitza C; Meier JJ
    Diabetes Obes Metab; 2021 Oct; 23(10):2344-2353. PubMed ID: 34189834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
    Astrup A; Carraro R; Finer N; Harper A; Kunesova M; Lean ME; Niskanen L; Rasmussen MF; Rissanen A; Rössner S; Savolainen MJ; Van Gaal L;
    Int J Obes (Lond); 2012 Jun; 36(6):843-54. PubMed ID: 21844879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.
    Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ
    Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists.
    Gill L; Mackey S
    J Womens Health (Larchmt); 2021 Jul; 30(7):1016-1027. PubMed ID: 33626287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial.
    Andersen E; Juhl CR; Kjøller ET; Lundgren JR; Janus C; Dehestani Y; Saupstad M; Ingerslev LR; Duun OM; Jensen SBK; Holst JJ; Stallknecht BM; Madsbad S; Torekov SS; Barrès R
    Hum Reprod; 2022 Jun; 37(7):1414-1422. PubMed ID: 35580859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liraglutide in the treatment of obesity.
    Ng SY; Wilding JP
    Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
    Ayers KL; Glicksberg BS; Garfield AS; Longerich S; White JA; Yang P; Du L; Chittenden TW; Gulcher JR; Roy S; Fiedorek F; Gottesdiener K; Cohen S; North KE; Schadt EE; Li SD; Chen R; Van der Ploeg LHT
    J Clin Endocrinol Metab; 2018 Jul; 103(7):2601-2612. PubMed ID: 29726959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment options for children with monogenic forms of obesity.
    Hainerová IA; Lebl J
    World Rev Nutr Diet; 2013; 106():105-12. PubMed ID: 23428688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel melanocortin 4 receptor (MC4R) gene mutation associated with morbid obesity.
    Mergen M; Mergen H; Ozata M; Oner R; Oner C
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3448. PubMed ID: 11443223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.